Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2741/S369PMID 23277048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

  2011cited by this paper
• Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect.

  2011cited by this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cited by this paper
• Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models

  2011cited by this paper
• Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.

  2011cited by this paper
• Dual inhibition of epidermal growth factor receptor and insulin‐like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma

  2011cited by this paper
• Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC).

  2011cited by this paper
• Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor

  2010cited by this paper
• Molecular Cancer apeutics apeutic Discovery pensatory Insulin Receptor ( IR ) Activation on Inhibition of lin-Like Growth Factor-1 Receptor ( IGF-1 R ) : Rationale Ther Cotargeting IGF-1 R and IR in Cancer

  2010influential reference
• Antisense oligonucleotide targeting of insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer

  2010cited by this paper
• Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

  2010cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts

  2010cited by this paper
• A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

  2010cited by this paper
• Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.

  2010cited by this paper
• R1507, a fully human monoclonal antibody targeting IGF‐1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

  2010cited by this paper
• A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

  2010cited by this paper
• Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.

  2010cited by this paper
• Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

  2010cited by this paper
• Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

  2009cited by this paper
• High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

  2009cited by this paper
• Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.

  2009cited by this paper
• Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

  2009cited by this paper
• Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

  2009cited by this paper
• Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

  2009cited by this paper
• The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

  2009cited by this paper
• A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

  2009cited by this paper
• Epidermal growth factor signalling and bone metastasis

  2009cited by this paper
• Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009influential reference
• Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

  2009cited by this paper
• AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

  2009cited by this paper
• The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.

  2008cited by this paper
• Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

  2008cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

  2008cited by this paper
• Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

  2008cited by this paper
• Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.

  2008cited by this paper
• Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation*

  2008influential reference
• Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

  2008cited by this paper
• Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

  2008cited by this paper
• Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

  2008cited by this paper
• Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.

  2008influential reference
• Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

  2008cited by this paper
• Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma.

  2008cited by this paper
• The Type 1 Insulin-Like Growth Factor Receptor Pathway

  2008cited by this paper
• Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance

  2008cited by this paper
• IMC-A 12 , a Human IgG 1 Monoclonal Antibody to the Insulin-Like Growth Factor IReceptor

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007influential reference
• IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

  2007cited by this paper
• Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

  2007cited by this paper
• Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

  2006cited by this paper
• Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours

  2006cited by this paper
• Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinib

  2006cited by this paper
• Growth factor receptor interplay and resistance in cancer.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.

  2006cited by this paper
• Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor

  2006cited by this paper
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

  2006cited by this paper
• Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis.

  2006cited by this paper
• Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

  2006cited by this paper
• EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib

  2006cited by this paper
• A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity*

  2005influential reference
• Microarray‐based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression

  2005cited by this paper
• Antibody-Mediated Cytolysis of Epidermal Growth Factor Receptor — Positive Human Uveal Melanoma Cells

  2005cited by this paper
• Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871

  2005cited by this paper
• Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

  2005cited by this paper
• A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk

  2005cited by this paper
• Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

  2005cited by this paper
• A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts

  2005cited by this paper
• A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer

  2005cited by this paper
• In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors

  2005cited by this paper
• Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.

  2005cited by this paper
• Growth hormone / insulin-like growth factor-1 axis during puberty.

  2005cited by this paper
• Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells.

  2005cited by this paper
• The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models.

  2005influential reference
• The insulin-like growth factor-I receptor as a target for cancer therapy

  2005cited by this paper
• Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

  2005cited by this paper
• Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth

  2004cited by this paper
• Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.

  2004cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk.

  2003cited by this paper
• Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics*

  2003cited by this paper
• Endometrial Cancer and the IGF System: A Case-Control Study in Greece

  2003cited by this paper
• The Insulin-Like Growth Factor (IGF) Family and Breast Cancer

  2003cited by this paper
• Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

  2003cited by this paper
• IGFBPs and Breast Cancer

  2003cited by this paper
• Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy

  2003cited by this paper
• Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden

  2002cited by this paper
• Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

  2002cited by this paper
• Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.

  2002cited by this paper
• Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells*

  2002cited by this paper
• Transport of insulin-like growth factor-I across endothelial cell monolayers and its binding to the subendothelial matrix.

  2002cited by this paper
• Metastasis: Dissemination and growth of cancer cells in metastatic sites

  2002cited by this paper

• Unveiling the antibreast cancer mechanism of Euphorbia hirta ethanol extract: computational and experimental study

  2024cites this paper
• Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

  2023cites this paper
• Topical ozone accelerates diabetic wound healing by promoting re-epithelialization via activation of IGF1R-EGFR signaling.

  2023cites this paper
• Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.

  2023cites this paper
• Evaluation of the cytotoxic activity of Tamarix articulata and its anticancer potential in prostate cancer cells

  2022cites this paper
• Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within

  2022cites this paper
• Highlights on Selected Growth Factors and their Receptors as Promising Anticancer Drug Targets.

  2021cites this paper
• 3-Acetyl-11-keto-β-boswellic acid inhibits cancer cell invasion and induces apoptosis in breast cancer cells by abrogating the EGFR-mediated PI3K/Akt pathway

  2020cites this paper
• Targeting micro-RNAs by natural products: a novel future therapeutic strategy to combat cancer.

  2020cites this paper
• Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy.

  2019cites this paper
• Molecular Targets of Active Anticancer Compounds Derived from Marine Sources

  2018cites this paper
• Running title : A framework for pathway inference and modelling Character count : 48856

  2017cites this paper
• The IGF axis in HPV associated cancers.

  2017cites this paper
• MicroRNA‑186 targets IGF‑1R and exerts tumor‑suppressing functions in glioma.

  2017cites this paper
• MicroRNA-187 inhibits tumor growth and metastasis via targeting of IGF-1R in hepatocellular carcinoma.

  2017cites this paper
• Integrating network reconstruction with mechanistic modeling to predict cancer therapies

  2016cites this paper
• PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells

  2016cites this paper
• Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma

  2016influential citation
• Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

  2015cites this paper
• MicroRNA-133a Suppresses Multiple Oncogenic Membrane Receptors and Cell Invasion in Non-Small Cell Lung Carcinoma

  2014cites this paper
• Identifying Molecular Mechanisms and Cellular Origins of Cancers of the Nervous System

  2013cites this paper